프로테나 코퍼레이션(PRTA)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $8.51 (+0.59%), 시가총액 $0.47B, 52주 최저~최고 $4.58 ~ $11.51.
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for th
프로테나 코퍼레이션의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
프로테나 코퍼레이션의 현재 주가는 $8.51 (+0.59%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
프로테나 코퍼레이션의 시가총액은 약 $0.47B입니다.
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline i